Vitamin D dependent effects of APOA5 polymorphisms on HDL cholesterol

Atherosclerosis

Volumn 222, Issue 1, 2012, Pages 167-174

  Shirts, Brian H ^a   Howard, Michael T ^a   Hasstedt, Sandra J ^a   Nanjee, M Nazeem ^a   Knight, Stacey ^a,b   Carlquist, John F ^a,b   Anderson, Jeffrey L ^a,b   Hopkins, Paul N ^a   Hunt, Steven C ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

Apolipoprotein A5; Cardiovascular disease risk; Causative variant; Gene environment interaction; HDL cholesterol; Triglyceride; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; APOLIPOPROTEIN A5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VITAMIN D;

ARTICLE; BINDING SITE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE REPLICATION; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RECEPTOR BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

AGED; APOLIPOPROTEINS A; BINDING SITES; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; GENE-ENVIRONMENT INTERACTION; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, CALCITRIOL; SEASONS; UTAH; VITAMIN D;

EID: 84862788698     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.02.030     Document Type: Article

References (32)

1. Lewington S., Whitlock G., Clarke R., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
2. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
3. Waterworth D.M., Ricketts S.L., Song K., et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol 2010, 23:23.
4. Ordovas J.M. HDL genetics: candidate genes, genome wide scans and gene-environment interactions. Cardiovasc Drugs Ther 2002, 16:273-281.
5. Ramagopalan S.V., Heger A., Berlanga A.J., et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010, 20:1352-1360. Epub 2010 Aug 1324.
6. Jorde R., Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011, 50:303-312. Epub 2011 May 2027.
7. Shahar D.R., Froom P., Harari G., Yerushalmi N., Lubin F., Kristal-Boneh E. Changes in dietary intake account for seasonal changes in cardiovascular disease risk factors. Eur J Clin Nutr 1999, 53:395-400.
8. Boullata, Vitamin J.I. D supplementation: a pharmacologic perspective. Curr Opin Clin Nutr Metab Care 2010, 13:677-684.
9. Williams R.R., Hunt S.C. Recruitment of members of high-risk Utah pedigrees. Control Clin Trials 1987, 8:105S-114S.
10. Willett W.C., Sampson L., Stampfer M.J., et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985, 122:51-65.
11. Shirts B.H., Hasstedt S.J., Hopkins P.N., Hunt S.C. Evaluation of the gene-age interactions in HDL cholesterol, LDL cholesterol, and triglyceride levels: the impact of the SORT1 polymorphism on LDL cholesterol levels is age dependent. Atherosclerosis 2011, 15:15.
12. Heard-Costa N.L., Zillikens M.C., Monda K.L., et al. NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. PLoS Genet 2009, 5:e1000539.
13. Higgins M., Province M., Heiss G., et al. NHLBI Family Heart Study: objectives and design. Am J Epidemiol 1996, 143:1219-1228.
14. Muhlestein J.B., Horne B.D., Bair T.L., et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001, 87:257-261.
15. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999, 69:842-856.
16. Levy D., Neuhausen S.L., Hunt S.C., et al. Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. Proc Natl Acad Sci U S A 2010, 107:9293-9298.
17. Sandelin A., Wasserman W.W., Lenhard B. ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res 2004, 32:W249-W252.
18. Fullerton S.M., Buchanan A.V., Sonpar V.A., et al. The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster. Hum Genet 2004, 115:36-56.
19. Wehmeier K., Beers A., Haas M.J., et al. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim Biophys Acta 2005, 1737:16-26.
20. Hasstedt S.J. jPAP: document-driven software for genetic analysis. Genet Epidemiol 2005, 29:1.
21. Jacques P.F., Sulsky S.I., Sadowski J.A., Phillips J.C., Rush D., Willett W.C. Comparison of micronutrient intake measured by a dietary questionnaire and biochemical indicators of micronutrient status. Am J Clin Nutr 1993, 57:182-189.
22. Consortium G.P. A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073.
23. Akhter J., Lu Y., Finlay I., Pourgholami M.H., Morris D.L. 1alpha,25-Dihydroxyvitamin D3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2. ANZ J Surg 2001, 71:414-417.
24. Nordestgaard B.G., Tybjaerg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol 2011, 22:113-122.
25. Vergeer M., Holleboom A.G., Kastelein J.J., Kuivenhoven J.A. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?. J Lipid Res 2010, 51:2058-2073.
26. National Heart, L., and Blood Institute (NHLBI) NIH stops clinical trial on combination cholesterol treatment. In, NIH, News, National Institutes of Health, 2011.
27. Tai E.S., Ordovas J.M. Clinical significance of apolipoprotein A5. Curr Opin Lipidol 2008, 19:349-354.
28. Forte T.M., Shu X., Ryan R.O. The ins (cell) and outs (plasma) of apolipoprotein A-V. J Lipid Res 2009, 50(Suppl):S150-S155.
29. Brown C.M., Rea T.J., Hamon S.C., et al. The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability. J Mol Med 2006, 84:561-572.
30. Hamon S.C., Kardia S.L., Boerwinkle E., et al. Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene cluster. Hum Hered 2006, 61:87-96.
31. Lai C.Q., Corella D., Demissie S., et al. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study. Circulation 2006, 113:2062-2070.
32. Guo S.W. Gene-environment interaction and the mapping of complex traits: some statistical models and their implications. Hum Hered 2000, 50:286-303.